Abstract
Introduction
Chronic immune stimulation plays an important role in atherogenesis 1 . Activated T cells are prominent components of human atherosclerotic lesions [2] [3] and also, blood samples from patients with coronary artery disease (CAD), in particular acute coronary syndromes (ACS),
show signs of T cell activation [4] [5] [6] . While much attention has been focused on the role of CD4 + T cells, the CD8 + T cell compartment has been less investigated. However, in human lesions, CD8 + T cells are almost as frequent as CD4 + T cells, thus not reflecting the CD4:CD8 ratio of about 2:1 normally seen in blood 7 . In addition, it was recently shown that human plaques contain more activated CD8 + T cells than activated CD4 + T cells 3 . A few earlier studies measuring the numbers of activated CD8 + T cells in the circulation of patients with CAD have
shown contradictory results [8] [9] .
A subpopulation of circulating T cells, the majority being CD8 + T cells, expresses the natural killer cell marker CD56. In infants, the numbers of circulating CD8 + CD56 + T cells are extremely low, but then increase with age 10 . The induction of CD56 has been shown to correlate with the loss of CD28, a hallmark of immunological aging [10] [11] , and furthermore, the conversion to a senescent T cell phenotype is accentuated by a common pathogen, namely cytomegalovirus (CMV) 12 . In addition, increased proportions of circulating CD8 + CD56 + T cells are described in chronic autoimmune diseases like rheumatoid arthritis, sarcoidosis and
Behcet´s uveitis 11, [13] [14] [15] . The expression of CD56 on CD8 + T cells has also been associated with disease activity 11, 16 . Still, the clinical relevance of accumulated CD8 + CD56 + T cells during aging and disease is far from clarified. CD56 + T cells are often described as cytolytic effector cells 17 but conversely, CD56 has emerged as a potential marker for CD8 + suppressor
T cells with anti-inflammatory potential [18] [19] . In vitro, CD56 + T cells have shown the capacity to produce both type 1 and type 2 cytokines 10, [15] [16] [20] [21] .
An increase in CD56 + T cells was recently reported in patients with acute myocardial infarction compared with healthy controls, independent of CMV seropositivity 22 . In an earlier cross-sectional study, we found that patients with stable CAD exhibited an increase in CD8 + T cells lacking CD28, a phenomenon that was not only determined by CMV seropositivity but also by CAD per se 23 . In the present study, we hypothesized that the distribution and phenotype of CD8 + CD56 + T cells in CAD patients would reflect disease activity, thereby changing over time. The proportions and phenotypic characteristics of CD8 + CD56 + T cells were therefore longitudinally investigated in ACS and SA patients before and up to 12 months after referral for coronary investigation. In order to further characterize the functional status of these cells, the cytokine profile was examined after stimulation ex vivo.
Methods

Subjects
The study population consisted of 30 patients with ACS, 34 patients with SA, and 36 healthy control subjects. Coronary angiograms were performed in all patients at day 1. Blood samples were always collected prior to coronary angiography, and in ACS patients within 24 h from admission. The patients were longitudinally followed, and after 3 months samples were collected in 16 ACS and 28 SA patients, and after 12 months in 15 ACS and 28 SA patients.
The ACS patients were included if they had a diagnosis of unstable angina/non-ST elevation myocardial infarction, with the diagnosis based on typical ECG-changes (ST-T segment depression and/or T-wave inversion) and/or elevated troponins. The SA patients included were referred for elective coronary angiography due to effort angina class II or III in accordance with Canadian Cardiovascular Society Classification and without any worsening of symptoms the latest 3 months. Patients were excluded if they had severe heart failure, immunologic disorders, neoplastic disease, evidence of acute or recent (<2 months) infection, recent major trauma, surgery or revascularization procedure, treatment with immunosuppressive or anti-inflammatory agents (except low-dose aspirin). The age and sex matched control subjects, randomly selected from a population based register representing the hospital recruitment area, were anamnestically healthy and received no medication. The study was conducted in accordance with the ethical guidelines of Declaration of Helsinki, and the research protocol was approved by the Ethical Review Board of Linköping University.
Written informed consent was obtained from all study participants.
Monoclonal antibodies and in vivo lymphocyte profiles
Lymphocyte subpopulations from peripheral blood were analyzed by 6-or 7-color combinations. Cells were stained with Annexin V-PE or the following monoclonal antibodies:
CD3-FITC (clone SK7), CD3-PerCP (clone SK7), CD4-APC (clone SK3), CD4-PE-Cy7 Biosciences, San José, CA, US.
As previously described 24 , whole blood and antibodies were incubated for 15 minutes at room temperature (RT), thereafter erythrocytes were lysed with FACS Lysing Solution (BD Biosciences) for 15 minutes at RT. Samples were analyzed on a FACSCanto II (BD Biosciences) equipped with 3 lasers, a blue 488 nm, a red 633 nm and a violet 405 nm.
Analysis of samples was stopped when 10 000 cells were collected in the lymphocyte gate.
Data were analyzed and subpopulations gated with FACSDiva 6.1.2 software (BD Biosciences).
Whole blood stimulation and detection of intracellular cytokines
Whole blood stimulation was performed in a subgroup of the study population, i.e. 9 ACS, 14 SA and 11 control subjects. For detection of intracellular cytokines, the protocol FastImmune (BD Biosciences) for whole blood stimulation was followed. In brief, heparinized whole blood was stimulated ex vivo for 6h at 37°C and 5% CO 2 with anti-CD28/CD49d (BD Biosciences), 50ng/ml phorbol 12-myristate 13-acetate (PMA; SIGMA, Saint Louis, MO, US), and 1µg/ml ionomycin (SIGMA) in presence of 10µg/ml brefeldin A (BD Biosciences). 
Results
The characteristics of patients and controls are listed in Table 1 . At day 1, 11 (32%) SA patients and 19 (63%) ACS patients underwent percutaneous coronary intervention while 16 (47 %) SA patients and 5 (17 %) ACS patients were referred for coronary bypass surgery.
Seven SA patients and 6 ACS patients did not undergo any vascular revascularization procedure. All patients were on low-dose aspirin and various combinations of -blockers, calcium-antagonists and nitrates. Compared with ACS patients, SA patients were to a larger extent long-term treated, i.e. > 2 months, with statins at day 1. However, at 3 months followup, 87 % of the SA patients and 94 % of the ACS patients received statin resulting in similar LDL cholesterol levels in both groups. The levels of CRP, IL-6 and IL-15 during the 12 month period of follow-up are given in Table 2 . Both SA and ACS patients exhibited higher levels of IL-6 at day 1. The levels declined significantly in both patient groups. At 12 months, the IL-6 levels in SA patients still remained at a significantly higher level compared with controls. The levels of CRP and IL-15 did not differ between groups at any time point except for higher levels in ACS patients at day 1. During follow-up, IL-6 levels in patients were significantly correlated with smoking (r = 0.32, p < 0.01), waist circumference (r = 0.38, p < 0.01) and hypertension (r = 0.28, p < 0.05). Follow-up CRP levels only showed correlations with waist circumference (r = 0.28, p < 0.05) while IL-15 lacked correlations with clinical variables. The prevalence of CMV seropositivity was similar in patients and controls.
The total numbers of leukocytes were significantly higher in both patient groups at day 1 ( 16 . Although it may be difficult to draw parallels between CAD and Behcet´s uveitis due to differences in immunopathology and immune-based therapy, the findings by Ahn et al 16 indicate that the expansion of CD56 on CD8 + T cells is not necessarily a permanent phenomenon.
CMV is a common life-long infection, usually asymptomatic, that is believed to influence atherogenesis and cardiovascular risk 27 . It is unique amongst herpesviruses by inducing senescence in T cells involving features like enhanced expression of natural killer cell markers and lack of CD28 12 . Accordingly, we found increased proportions of CD8 + CD56 + T cells in CMV seropositive individuals although CMV seropositivity alone could not explain the expansion of the CD8 + CD56 + T cell subset in blood of CAD patients. Our finding is in agreement with a recent study by Romo et al 22 reporting that proportions of CD56 + T cells were increased in patients with acute myocardial infarction compared with healthy controls, independent of age, sex, conventional risk factors and CMV seropositivity. Thus we now extend their finding by demonstrating that this phenomenon is not only restricted to patients with acute events, but also includes SA patients and furthermore that it persists for one year.
The early activation marker CD69 was more frequently expressed by CD8 + CD56 + T cells than CD8 + CD56 -T cells while the expression of HLA-DR did not differ. This is in agreement with a study by Kelly-Rogers et al 21 , showing that human CD8 + CD56 + T cells were more prone to upregulate CD69 upon stimulation than were CD8 + CD56 -T cells. The same authors
showed that HLA-DR was equally induced on both CD8 + T cell subsets. As expected, we found a lack of CD28 on the majority of CD8 + CD56 + T cells. The reciprocal expression of CD56 and CD28 on peripheral T cells has been described by several [10] [11] 17 and is considered an indicator of T cell senescence. Resistance to apoptosis is considered another feature of senescent CD8 + T cells 28 instability. Due to its short half-life, the cytokine is difficult to detect in plasma but an enhanced expression of IFN-γ in circulating cells of CAD patients, in particular ACS patients, has been reported by several investigators [5] [6] . Interestingly, plasma levels of cytokines belonging to the IFN-γ axis have also been associated with increased mortality and morbidity after 1-year follow-up in both SA and ACS patients 29 and recently, a study by Pedersen et al 30 showed that systemic markers of IFN-γ activity predicted long-term prognosis in SA patients. It should be notified that in both these studies, as in our study, the majority of patients were treated with statin, a drug that is associated with T cell inhibitory effects 31 . b Prior coronary event: prior ACS and/or coronary revascularization.
* P < 0.05 compared with controls, # P < 0.01 compared with controls, ‡ P < 0.001 compared with controls Differences within groups (from day 1 to 12 months) are given in the right column.
* P < 0.05 compared with controls, ‡ P < 0.001 compared with controls Table 3 . Numbers and proportions of CD8 + and CD4 + T cell subsets 
